Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone.
D000293:Adolescent; D000328:Adult; D001120:Arginine; D001769:Blood; D018288:Carcinoma, Small Cell / Q000473:pathology; D003520:Cyclophosphamide / Q000627:therapeutic use; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000473:pathology; D008175:Lung Neoplasms / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009994:Osmolar Concentration; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D011241:Prednisone / Q000627:therapeutic use; D011863:Radioimmunoassay; D012964:Sodium / Q000097:blood / Q000652:urine; D014556:Urine; D014667:Vasopressins / Q000097:blood / Q000378:metabolism*; D014750:Vincristine / Q000009:adverse effects* / Q000627:therapeutic use
D014667:Vasopressins; D014750:Vincristine; D003520:Cyclophosphamide; D001120:Arginine; D012964:Sodium; D011241:Prednisone